Startup Rise EU News’ Post

🔥 𝗗𝗲𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗪𝗲𝗲𝗸 🔥 #25: iOnctura Raises EUR80M in Series B Financing The funding round was led by Syncona Limited , with contributions from the European Innovation Council Fund and existing investors, including M Ventures, Inkef Capital, Vi Partners, Schroders Capital, and 3B Future Health Fund I & II. The company plans to use the funds to expedite the development of its lead asset, roginolisib, for treating uveal melanoma and various other oncology indications. iOnctura aims to begin trials for additional cancer indications, such as non-small cell lung cancer and primary myelofibrosis, by the end of 2024. 👏 𝘊𝘰𝘯𝘨𝘳𝘢𝘵𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴 𝘵𝘰 𝘵𝘩𝘦 𝘦𝘯𝘵𝘪𝘳𝘦 𝘵𝘦𝘢𝘮! News Link ➡️ https://lnkd.in/eyNaCha4 Giusy Di Conza Alessio Bevilacqua David Seeberger Kiran Roest Lars van der Veen Diego Braguglia Thijs Cohen Tervaert Berthold Baurek-Karlic Julia Gülden-Zeisberger Denis Voldman Makar Vergovskiy Iman Saïd Philipp Sakuler #DealMatrix #iOnctura #Startups #DealOfTheWeek #Deals #Investments

Cancer detection redefined: Epi One relaunches on StartEngine. - Not incremental progress—a fundamental shift in cancer detection - Led by former American Cancer Society Board Chair - Co-founders: Seasoned scientists from Memorial Sloan-Kettering - Pre-revenue opportunity in early-stage cancer diagnostics - Increased investor confidence through StartEngine broker-dealer Our mission: Transform cancer care with entirely different technology. Learn more and invest: https://lnkd.in/eYrJiFKJ This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. #equitycrowdfunding #funding #seedcapital #regCF #EpiOne #EarlyCancerDetection #SaveLivesWithScience

Epi One aims to offer accurate and affordable early cancer detection using what we believe is a groundbreaking diagnostic testing platform. We seek to make cancer less scary by detecting it early enough to cure and accurately enough to treat appropriately. We would like to give everyone the chance to invest and own a piece of Epi One, which is why we have been working with StartEngine, one of the leading equity crowdfunding platforms. Although we cannot share all of the information yet, you can click on the link below to learn more. If you are interested, you can add your name to the list of potential future investors and get notified immediately when we have updates to share with you. Essentially, you can make a reservation to potentially become an investor in the future. Also, please see this important message below: NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED, AND IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT IS FILED AND ONLY THROUGH AN INTERMEDIARY’S PLATFORM. AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND. "RESERVING" SECURITIES IS SIMPLY AN INDICATION OF INTEREST. At this point, if you are interested, you can only get your name on the list for this potential future offering and indicate how much you might like to invest if this offering does indeed go live. Please click below to learn more and don’t miss the short video at the top. https://lnkd.in/eYrJiFKJ

Absolutely thrilled to celebrate the incredible achievements of my fellow #MC23 alum, Judit Giró Benet of The Blue Box Biomedical Solutions, as we graduate from the CancerX Accelerator! 🎉🚀 CancerX Moonshot, a public-private partnership announced by The White House, serves as a national accelerator dedicated to fostering innovation in the battle against cancer. It’s inspiring to see talented founders leading the charge! 🎓 Both Judit and I had an amazing journey with the MassChallenge 2023 U.S. Early Stage Program, and it’s exciting to see our continued impact. 🥣 Oatmeal Health is not only a part of the 2023 HealthTech Program but also a proud finalist. We aim to empower health equality through AI-enabled cancer screening and early detection. Our cutting-edge platform focuses on underserved FQHC patient populations, offering expert primary care support, comprehensive radiology risk assessments, and the latest AI and biotech advancements for early diagnosis—all at no cost, fully funded by Medicare/Medicaid. Now that we are done with this amazing program, we are raising capital to expand services and our technology, reach out to me to learn more about the opportunity - [email protected] Let's continue to support and spread the word to #Founders innovating in the fight against #cancer. Together, we can drive the future of #healthtech and make a difference in #healthcare. Learn more about these inspiring ventures here: ⛑️ https://hubs.ly/Q02JQsLh0 And here www.oatmealhealth.com #innovation #nonprofit #zeroequity #accelerators #startups #founders #healthtech #healthcare

Epi One is developing innovative cancer detection technology with the potential to impact many lives. Our dedicated team, led by a CEO with personal experience in cancer's effects, is working to advance early diagnosis methods. We're part of a growing market for cancer diagnostics, and we've already achieved promising results. By investing in Epi One, you have the opportunity to support important research in healthcare while participating in our company's potential growth. We invite you to learn more about our work and consider joining us in our efforts to improve cancer detection. https://lnkd.in/eYrJiFKJ This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. #equitycrowdfunding #funding #seedcapital #regCF #EpiOne #EarlyCancerDetection #SaveLivesWithScience

Transforming cancer detection with affordability and accessibility! 💡 On this episode of Superpowers for Good, Jonathan Cohen shares how 20/20 GeneSystems is making early cancer testing available to everyone with their innovative OneTest. By leveraging equity crowdfunding, they’re also democratizing biotech investments. Join the mission to save lives and create impact! 🔗 Post link in the comments. #CancerDetection #AffordableHealthcare #EquityCrowdfunding #InnovationForGood #SuperpowersForGood #EarlyDetection #AI #HealthInnovation

Transforming cancer detection with affordability and accessibility! 💡 On this episode of Superpowers for Good, Jonathan Cohen shares how 20/20 GeneSystems is making early cancer testing available to everyone with their innovative OneTest. By leveraging equity crowdfunding, they’re also democratizing biotech investments. Join the mission to save lives and create impact! 🔗 Post link in the comments. #CancerDetection #AffordableHealthcare #EquityCrowdfunding #InnovationForGood #SuperpowersForGood #EarlyDetection #AI #HealthInnovation

🎉 Thrilled to share that Oncoliq has been featured in a Venture Capital Post article! 🚀 As we focus on launching our product by early 2026, we want to keep sharing the importance of early detection in significantly improving survival rates. Current screening methods are inaccessible to many or not sensitive enough to catch cancers early 👩🔬🏥. Oncoliq's groundbreaking blood test detects microRNA, tiny molecules in the early stages of tumor development. This is precisely what differentiates us from competitors who rely on detecting ctDNA, which only appears in the bloodstream during later stages of cancer. "At Oncoliq, we've developed a solution that can change the landscape of cancer diagnostics, making it possible to detect cancer early, easily, and at a low cost," says Marina Simian, to the Venture Capital Post team. 🚀 Join Oncoliq if you feel inspired about shaping the future of cancer detection and saving lives! Read the full article here and comment your thoughts!👉 https://lnkd.in/ddxKA5gJ Thank you [Venture Capital Post] #Oncoliq #Biotechnology #EarlyDetection #LiquidBiopsy #HealthTech #InnovationInHealthcare #VentureCapital #HealthcareInvesting #CancerDiagnosis #CancerMortality #HealthStartups

Exciting News! I’m pleased to let my LinkedIn network know that I have recently joined Senoguard as CFO. Senoguard is at the forefront of cancer innovation, developing a patented medical device aimed at improving breast cancer treatment. Our goal is to provide a more accessible and cost-effective alternative to traditional therapies, especially in underserved areas. With October being Breast Cancer Awareness Month, this mission feels even more critical. I’m proud to be part of a team that is dedicated to making a real difference in the fight against breast cancer. We are currently running a crowdfunding campaign on WeFunder, and I would love for you to check it out and support our mission to help make this critical treatment more available to those who need it most. Explore our campaign here: https://lnkd.in/eY9yj4h7 SEC Disclosure: We are 'testing the waters' to gauge investor interest in an offering under Regulation Crowdfunding. No money or other consideration is being solicited. If sent, it will not be accepted. No offer to buy securities will be accepted. No part of the purchase price will be received until a Form C is filed and only through Wefunder’s platform. Any indication of interest involves no obligation or commitment of any kind. #Senoguard #BreastCancerAwarenessMonth #BreastCancerTreatment #MedicalDevices #Innovation #Healthcare #Crowdfunding #WeFunder #FightCancer

#Update Celesta Capital led the Series A round, with participation from Tenacity Ventures, Cedars-Sinai, Eragon Ventures, and Singularity Ventures. OneCell Diagnostics Inc., a Pune-based cancer diagnostics startup, has raised USD 16 million in Series A funding led by Celesta Capital. This funding will fuel the US expansion of OncoIndx Alfa, a next-generation liquid biopsy test. This innovative test leverages advanced technologies to detect circulating tumor cells, enabling precise cancer diagnosis and monitoring. OneCell Diagnostics Inc.'s B2B2C model delivers these tests through oncologists and hospitals. With a strong team, strategic partnerships, and a focus on personalized cancer care, OneCell Diagnostics Inc. aims to revolutionize global cancer diagnostics. Read the story: https://ow.ly/FszE50Ucvsa Mohan Uttarwar, Co-founder and CEO, OneCell Diagnostics Inc. #StartupFunding #CancerDiagnostics #SeriesAFunding #Biotech #LiquidBiopsy #HealthTech #Oncology #PersonalizedMedicine #InnovationInHealthcare #Diagnostics